Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 15;38:309. doi: 10.1186/s13046-019-1294-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 8 — The Fiduxosin and SB206553 APE1/NPM1 interaction-inhibitors sensitize only HCC70 cells to platinum compounds treatment. Histograms show the effect of co-treatments with CDDP (a, c, d) or CBDCA (b-e, f) and APE1/NPM1 inhibitors including Fiduxosin (a, b, d, e) and SB206553 (c), on HCC70 cells viability. Analysis was carried on for 48 h of treatment (a,b,c) or 72 h of treatment (d, e). Values express the mean viability ± SD from at least three independent replicates. Each value is normalized to the untreated condition. *p < 0.05, **p < 0.001, ***p < 0.0001. A Bliss analysis, performed on these data, confirmed the existence of an additive effect of the APE1/NPM1 inhibitors on HCC70 cell line (data not shown)